Titan Pharmaceuticals
 | |
| Company type | Public |
|---|---|
| Nasdaq: TTNP | |
| Industry | Pharmaceuticals |
| Headquarters | California |
Key people | |
| Revenue |  $1.7 million [2] |
| Total assets | $8.4 million [2] |
Number of employees | 14 (Nov 2018) |
| Website | titanpharm |
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds.[3] In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.[2][4]
Titan's principal asset is Probuphine,[5][6] a slow-release implant formulation of buprenorphine[7] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016.[8] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization.[6]
History
[edit]As of its November 14th earnings call, Titan Pharmaceuticals is on track to commercialize its opioid addiction solution at a valuation between $75 and $100 million.[9]
References
[edit]- ^ "Titan Strengthens Executive Leadership Team With Appointment Of Chief Commercial Officer". Titan Pharmaceuticals, Inc. 2 October 2018.
- ^ a b c "Titan Pharmaceuticals Reports Third Quarter 2018 Financial Results". Titan Pharmaceuticals, Inc. 14 November 2018.
- ^ "Titan Pharma (TTNP) Prices $9.5M Public Offering".
- ^ "Germany's Merck KGaA taking over Molteni Pharma of Italy - Pharmaceuti". www.thepharmaletter.com.
- ^ "Technology". Titan Pharmaceuticals, Inc.
- ^ a b "Annual Reports". Titan Pharmaceuticals, Inc.
- ^ Solof, Barry (2013). The therapist's guide to addiction medicine a handbook for addiction counselors and therapists. New York: Central Recovery Press, LLC. p. 98. ISBN 9781937612443. Retrieved 21 September 2015.
- ^ "Press Announcements - FDA approves first buprenorphine implant for treatment of opioid dependence". www.fda.gov. Retrieved 26 May 2016.
- ^ "Titan Pharmaceuticals Third Quarter 2018 Financial Results". www.webcaster4.com.
External links
[edit]
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |